AβPP (9E136)
ANTIBODY polyclonal manufacturer Cat# LS-C92122<br />manufacturer: LifeSpan Biosciences liquid, supernatant APP IgG APP, APLP, AICD Autogen Bioclear Rabbit Human AβPP http://alzforum.org/res/com/ant/default.asp?antibodyID=35374
SEARCH RESULTS
330986 RESULTS
AβPP (1B11F3)
ANTIBODY monoclonal 1B11F3 manufacturer Cat# LS-C82076<br /> manufacturer: LifeSpan Biosciences immunogen = Ni-NTA purified truncated recombinant APP expressed in E. coli strain BL21 (DE3) liquid, ascites, PBS, azide APP IgG<sub>2a</sub>, κ APP,
AβPP
ANTIBODY polyclonal manufacturer Cat# LS-C53415<br /> manufacturer: LifeSpan Biosciences immunogen = peptide corresp. to aa residues from the C-terminal region of rat APP liquid, affinity purified APP APP, APLP, AICD Autogen Bioclear Rabbit Dog Human Mouse R
AβPP
ANTIBODY polyclonal manufacturer Cat# LS-C68984<br /> manufacturer: LifeSpan Biosciences immunogen = synthetic peptide corresp. to aa residues G L M V G G V V liquid, serum, unpurified minimal cross-reactivity with abeta 40 APP, APLP, AICD Autogen Bioclear R
α-Synuclein, C-term
ANTIBODY polyclonal laboratory α-Synuclein, 111-131 <br />(<a href="http://som.flinders.edu.au/FUSA/NEUROSCIENCE/park.htm" target="_new">W.P. Gai</a>, Department of Human Physiology and Centre for Neuroscience, Flinders Univer
PAPER Westfall JE, Hoyt C, Liu Q, Hsiao YC, Pierce EA, Page-McCaw PS, Ferland RJ
Retinal degeneration and failure of photoreceptor outer segment formation in mice with targeted deletion of the Joubert syndrome gene, Ahi1.
J Neurosci. 2010 Jun 30;30(26):8759-68. PubMed: 20592197PAPER Vraneković J, Babić Bozović I, Starcević Cizmarević N, Buretić-Tomljanović A, Ristić S, Petrović O, Kapović M, Brajenović-Milić B
Functional inference of methylenetetrahydrofolate reductase gene polymorphisms on enzyme stability as a potential risk factor for Down syndrome in Croatia.
Dis Markers. 2010;28(5):293-8. PubMed: 20592453PAPER Ninan I, Bath KG, Dagar K, Perez-Castro R, Plummer MR, Lee FS, Chao MV
The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus.
J Neurosci. 2010 Jun 30;30(26):8866-70. PubMed: 20592208PAPER Smith TH, Sim-Selley LJ, Selley DE
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
Br J Pharmacol. 2010 Jun;160(3):454-66. PubMed: 20590557PAPER Scotter EL, Abood ME, Glass M
The endocannabinoid system as a target for the treatment of neurodegenerative disease.
Br J Pharmacol. 2010 Jun;160(3):480-98. PubMed: 20590559PAPER Dubois-Dauphin ML, Toni N, Julien SD, Charvet I, Sundstrom LE, Stoppini L
The long-term survival of in vitro engineered nervous tissue derived from the specific neural differentiation of mouse embryonic stem cells.
Biomaterials. 2010 Sep;31(27):7032-42. PubMed: 20591476PAPER Chiocco MJ, Zhu X, Walther D, Pletnikova O, Troncoso JC, Uhl GR, Liu QR
Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease.
Subst Use Misuse. 2010 Sep;45(11):1809-26. PubMed: 20590401PAPER Mozer AB, Whittemore SR, Benton RL
Spinal microvascular expression of PV-1 is associated with inflammation, perivascular astrocyte loss, and diminished EC glucose transport potential in acute SCI.
Curr Neurovasc Res. 2010 Aug;7(3):238-50. PubMed: 20590523PAPER Popa-Wagner A, Pirici D, Petcu EB, Mogoanta L, Buga AM, Rosen CL, Leon R, Huber J
Pathophysiology of the vascular wall and its relevance for cerebrovascular disorders in aged rodents.
Curr Neurovasc Res. 2010 Aug;7(3):251-67. PubMed: 20590524PAPER Bloch MJ, Basile JN
Angiotensin receptor blocker use may decrease the incidence and progression of Alzheimer's disease and dementia in older men but the strength of the evidence is questionable.
J Clin Hypertens (Greenwich). 2010 Jun;12(6):444-6. PubMed: 20591090Current Filters
No filters selected